检索结果-南通市图书馆

联合应用卡铂与紫杉醇治疗进展性和复发性宫颈癌:英国哥伦比亚癌症中心的治疗经验

世界核心医学期刊文摘（妇产科学分册） 2005年第11期1卷 38-38页

作者： Tinker A.V. Bhagat K. Swenerton K.d. Hoskins P.J. 王颖 Peter Maccallum cancer centre St. Andrew' s Place East Melbourne Vic. 3002 Australia

Background. One of the most active chemotherapy combinations in advanced or recurrent cervical cancer is cis-platin-paclitaxel. However, this palliative regimen is associated with significant toxicity. carboplatin-paclitaxel is thus an attractive option. Methods. Patients with advanced or recurrent carcinoma of the cervix treated with carboplatin-paclitaxel from April 2000 were included in the study. Starting doses of carboplatin-paclitaxel were: AUc 5-6 and 155-175 mg/m2, respectively, repeated every 28 days. Results. Twenty-five women treated with this combination were identified. Twenty-three women (92% ) had prior treatment with pelvic radiotherapy and 14 (56% ) had had concurrent radio-sensitizing cisplatin. There was a 20% PR and a 20% cR rate (10/25). The median progression-free survival for the entire group was 3 months. Responders had a median PFS of 16 months. Fourteen patients (56% ) had died of disease progression. The median overall survival (OS) was 21 months. common toxicities included: grade 1 or 2 anemia, 68% ; grade 3 or 4 anemia, 32% ; grade 3 or 4 neutropenia, 32% ; and grade 1 or 2 peripheral neuropathy, 24% . EcOG PS did not change significantly while on treatment. Eighty-four percent of treatments were delivered on time, and 96% at full dose. conclusions. carboplatinpaclitaxel is an active combination in advanced and recurrent cervical cancer. In this predominantly pre-irradiated group, the combination was deliverable, well tolerated, and the most commonly observed toxicity was anemia.1078. A phase Ⅱ evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: A Gynecologic Oncology Group study Grendys jr. E.c./Blessing J.A./Burger R./Hoffman J. E.c. Grendys jr., Florida Gynecologic Oncology, 2780 cleveland Avenue, Fort Myers, FL 33901, United States -GYNEcOL. ONcOL. 2005, 98/2 (249-253) Objective. A phase Ⅱ study was conducted to determine the efficacy of single agent flavopiridol therapy in patients with recurrent or pers

关键词：癌症中心联合方案放疗史毒性反应增敏剂存活期联合用药反应率癌症进展

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：